The Continuing Evolution of Therapy in First Relapse/Refractory Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Monitoring Patients With Multiple Myeloma

Multiple Options at First Relapse

Therapy Selection Considerations

Recent Phase 3 Trials in R/R MM

Alternative Approaches

Case #1: Carol

Case #1: Next Steps

Toxicity Considerations With Newer Agents

Case #2: Sally

Case #2: Next Steps

Possible Treatment Strategies

Toxicity Considerations With Newer Agents

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)